1 completed, 1 terminated, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow MSI: new trials by email Literature Review of MSI trials Research Report on MSI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer Monalizumab/MEDI5257 - MSI, dMMR Colorectal Cancer | Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2023-12-01 | 2026-04-06 | |
| Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer FOLFOX regimen, FOLFIRI Protocol, Avelumab - Metastatic Colorectal Cancer, MSI | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 132 | 2018-04-24 | 2025-06-29 |
| Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Atezolizumab, Bevacizumab - MSI, ColoRectal Cancer | Phase 2 | Terminated | Vall d'Hebron Institute of Oncology | 46 | 2017-11-24 | 2025-10-01 |
Colorectal Neoplasms (2) · Activated Protein C Resistance (1) · Neoplasms (1)
Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Rectal Diseases (2) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1)
Bevacizumab (2) · Cetuximab (1) · Folfox protocol (1) · IFL protocol (1) · Panitumumab (1) · aflibercept (1) · atezolizumab (1) · avelumab (1) · monalizumab (1)
Assistance Publique - Hôpitaux de Paris (1) · Federation Francophone de Cancerologie Digestive (1) · Vall d'Hebron Institute of Oncology (1)
France (2) · Belgium (1) · Italy (1) · Netherlands (1) · Spain (1)
Josep Tabernero Caturla, Prof (1) · Julien Taieb, Pr (1)
2016 (1)